Monte Rosa Therapeutics bounded higher on Monday, as shares nearly doubled on a deal with Novartis to develop treatments for ...

An Italian rescue helicopter of Italy has crashed high up on Monte Rosa, on the Swiss-Italian border. Miraculously, no one on board was injured. The helicopter was responding to an SOS when it cra ...

“Last year was transformative for Monte Rosa, with significant validation of our capabilities to design and develop ‘only-in-class’ MGDs for previously undruggable targets across a broad ...

So, the natural question for Monte Rosa Therapeutics (NASDAQ:GLUE) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as ...

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership ...

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...

Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics (GLUE) to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock’s upside is ...

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions. Vandana Singh Why Westport Fuel Systems Shares Are Trading ...

BOSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...

Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.